Article

Management of narcolepsy during pregnancy.

Sleep-Wake Disorders Center, Montefiore Medical Center, 111 East 210th St., Bronx, NY 10467, United States. Electronic address: .
Sleep Medicine (Impact Factor: 3.1). 02/2013; DOI: 10.1016/j.sleep.2012.11.021
Source: PubMed

ABSTRACT BACKGROUND: The management of pregnancy in patients with narcolepsy poses many questions regarding therapy, including the risk to the mother and fetus related to the disease, potential risks at the time of conception, the risk to both the mother and the fetus of the medications used to treat narcolepsy, and the risk to the infant from medications that might be secreted in breast milk. There are no detailed practice parameters on the treatment of narcolepsy patients during pregnancy. We surveyed narcolepsy specialists from around the world to determine their clinical approach to the management of patients with narcolepsy at the time of conception, during pregnancy and while breastfeeding. METHODS: Survey invitations were sent via e-mail to 75 clinicians worldwide between 2/2011 and 3/2011 with 34 responses (USA, n=10; Brazil, n=3; Czech Republic, n=2; France, n=2; Italy; n=2; Netherlands, n=2; Canada, n=1; Denmark, n=1; Finland, n=1; Germany, n=1; Japan, n=1; Spain, n=1; unknown n=7). Responders who completed the survey had 20years (median range, 5-35) of experience in sleep medicine practice with a median number of five narcolepsy patients seen per week. The number of pregnant narcoleptic patients followed per physician was five (median range 1-40). RESULTS: The survey results indicated that the management of patients with narcolepsy varies greatly from clinician to clinician and from country to country. The majority of the clinicians stopped the narcolepsy medications at the time of conception, during pregnancy, and during breastfeeding some reduced the dose and others did not change the dosage, depending on the particular medication. CONCLUSIONS: The findings from our survey and literature review suggest that the perceived risks of narcolepsy medication during pregnancy to the mother and the fetus usually are overestimated, as the risk for teratogenic effects from narcolepsy medications in therapeutic doses is essentially nonexistent. However, the potential for rare complications during pregnancy and congenital abnormalities cannot be excluded. Most narcolepsy patients have vaginal delivery without complications. In rare cases patients had cataplexy that interfered with delivery, but if caesarian is required there appears to be no increased anaesthetic or surgical risks. Further prospective information for the appropriate treatment of narcolepsy patients during pregnancy is needed.

0 Bookmarks
 · 
250 Views
  • Article: Narkolepsie
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Narkolepsie ist eine seltene Erkrankung. Die klassische Form umfasst die 4 Symptome exzessive Tagesmüdigkeit, Kataplexie, Schlaflähmung (Schlafparalyse) und hypnagoge Halluzinationen. Als Modellerkrankung nimmt sie in der Neurologie und Schlafmedizin eine bedeutende Rolle ein, da sie alle Übergänge vom Wach- in die Schlafzustände, Non-REM und REM aufweist. Bei Narkolepsiepatienten findet sich eine verringerte Zahl von hypokretinproduzierenden Neuronen im Hypothalamus und entsprechend ist der Hypokretinspiegel im Liquor erniedrigt. Das Neuropeptid Hypokretin (Orexin) besitzt Steuerfunktionen des Schlaf-Wach-Zyklus, der Regulation des autonomen Nervensystems, der Motorik und der metabolischen Prozesse. Dass die Narkolepsie noch immer zu spät diagnostiziert wird, ist in der modernen Medizin kaum nachvollziehbar. Möglicherweise ist die hohe Assoziation mit anderen Schlaf-Wach-Störungen hierfür verantwortlich. Genomweite Analysen konnten zeigen, dass Autoimmunmechanismen wesentlich an der Entstehung der Narkolepsie beteiligt sind. Hiervon sind die HLA-Assoziation mit inzwischen bekannten Allelen für Suszeptibilität und Protektion von allen bisher beschriebenen Assoziationen am wichtigsten. Bildgebende Verfahren zeigen auch neurodegenerative Veränderungen, sodass weiterhin eine multifaktorielle Ätiopathogenese wahrscheinlich ist. Das häufige Auftreten metabolischer Störungen ist noch nicht hinreichend geklärt. Die Früherkennung der Narkolepsie birgt neben den Möglichkeiten, den Betroffenen durch angemessene Therapie ein fast normales Leben zu ermöglichen, auch die Option einer immunmodulierenden Therapie, mit der Chance die Narkolepsie zu heilen.
    Der Nervenarzt 01/2014; 85(1). · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sleep disturbances are common in pregnancy and may be influenced by a multitude of factors. Pregnancy physiology may predispose to sleep disruption but may also result in worsening of some underlying sleep disorders, and the de novo development of others. Apart from sleep disordered breathing, the impact of sleep disorders on pregnancy, fetal, and neonatal outcomes is poorly understood. In this article, we review the literature and discuss available data pertaining to the most common sleep disorders in perinatal women. These include restless legs syndrome, insomnia, circadian pattern disturbances, narcolepsy, and sleep-disordered breathing.
    Clinics in Chest Medicine 09/2014; · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Narcolepsy is a rare disorder classified as hypersomnia of central origin. Its core symptoms are excessive daytime sleepiness (EDS) and cataplexy. Associated symptoms, hypnagogic hallucinations, sleep paralysis, automatic behavior, and sleep fragmentation, are unspecific. Genetic, autoimmune, and environmental factors contribute to hypocretin deficiency. Areas covered: This article focuses on therapies for narcolepsy symptoms and comorbid disorders. Despite the enormous increase of knowledge about narcolepsy's pathologies no substance has been developed that can cure the disease. So far hypocretin substitution is not available. Substances targeting the autoimmune mechanism have failed to show objective improvement despite subjective improvement. The standard medication in adults comprises stimulants and anticataplectics. Only few substances are capable of improving core and associated symptoms. Within the last years, only modafinil and its enantiomer armodafinil and sodium oxybate have been approved as new substances. Expert opinion: The choice of stimulants to treat excessive daytime sleepiness in narcolepsy needs to be expanded and anticataplectic medication needs to be approved for the indication. Head-to-head comparisons between the established medications, studies of high evidence in older non-evidence-based medications, in children, pregnant women, and of behavioral therapy need to be performed including the long-term effects on metabolic and cardiovascular risks. Narcolepsy is a model disease for so many sleep disorders, among which it has the most severe daytime sleepiness. New insights into its etiology have advanced sleep medicine immensely. Still it stays an orphan in terms of treatment options which are challenging because narcolepsy covers so many symptoms from neuropsychological metabolic-, cardiovascular-, endocrinological-, movement disorders, and parasomnias to name a few.
    Expert Opinion on Orphan Drugs. 11/2013; 1(12).